Clinical implications of the Third Universal Definition of Myocardial Infarction

Heart

Volumn 100, Issue 5, 2014, Pages 424-432

  White, Harvey D ^a   Thygesen, Kristian ^b   Alpert, Joseph S ^c   Jaffe, Allan S ^d  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TROPONIN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOPSY; CARDIAC IMAGING; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OCCLUSION; CORONARY ARTERY SPASM; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE BLOOD FLOW; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE OXYGEN CONSUMPTION; HEART REINFARCTION; HUMAN; OXYGEN SUPPLY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STENT THROMBOSIS; T WAVE;

MYOCARDIAL ISCHAEMIA AND INFARCTION (IHD);

ELECTROCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; TERMINOLOGY AS TOPIC;

EID: 84896716780     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302976     Document Type: Article

References (20)

1. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC-ACC-AHA-WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38. (Pubitemid 47616190)
2. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.
3. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-13.
4. Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 2008;118:2200-6.
5. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011;57:2406-8.
6. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations. J Am Coll Cardiol 2012;60:2427-63.
7. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
8. Jaffe AS, Apple FS, Morrow DA, et al. Being rational about (im) precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. Clin Chem 2010;56:941-3.
9. Biener M, Mueller M, Vafaie M, et al. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol 2012 [Epub ahead of print]
10. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31:2197-204.
11. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
12. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84.
13. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-64.
14. White HD, Reynolds HR, Carvalho AC, et al. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the occluded artery trial (OAT) cohort. Am Heart J 2012;163:563-71.
15. Jaffe AS, Apple FS, Lindahl B, et al. Why all the struggle about CK-MB and PCI? Eur Heart J 2012;33:1046-8.
16. White HD. The prequel: defining prognostically important criteria in the periprocedural PCI troponin saga. Circ Cardiovas Intervent 2012;5:142-5.
17. Leonardi S, Thomas L, Neely ML, et al. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. J Am Coll Cardiol 2012;60:2296-304.
18. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163:182-90 e4.
19. Bhatt DL, Stone GW, Mahaffey KW, et al. for the CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013; 368:1303-13.
20. Mendis S, Thygesen K, Kuulasmaa K, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol 2011;40:139-46.